 Melanie Everitt
Concepts (313)
Concepts are derived automatically from a person's publications.
Concepts are listed by decreasing relevance which is based on many factors, including how many publications the person wrote about that topic, how long ago those publications were written, and how many publications other people have written on that same topic.
| Name |
Number of Publications
|
Most Recent Publication
|
Publications by All Authors
|
Concept Score
|
Why?
|
|---|
| Heart Transplantation | 61 | 2025 | 736 | 9.510 |
Why?
| | Graft Rejection | 25 | 2025 | 540 | 4.140 |
Why?
| | Heart Defects, Congenital | 14 | 2023 | 914 | 2.170 |
Why?
| | Cardiomyopathies | 11 | 2024 | 338 | 2.080 |
Why?
| | Waiting Lists | 13 | 2025 | 263 | 1.480 |
Why?
| | Cardiomyopathy, Dilated | 8 | 2024 | 359 | 1.320 |
Why?
| | Registries | 17 | 2024 | 2385 | 1.270 |
Why?
| | Fontan Procedure | 5 | 2023 | 191 | 0.970 |
Why?
| | Antibodies | 8 | 2022 | 403 | 0.940 |
Why?
| | Heart Diseases | 6 | 2019 | 350 | 0.940 |
Why?
| | Survival Rate | 20 | 2025 | 2092 | 0.920 |
Why?
| | Heart Failure | 14 | 2024 | 2323 | 0.890 |
Why?
| | Child | 56 | 2025 | 22657 | 0.860 |
Why?
| | Extracorporeal Membrane Oxygenation | 2 | 2021 | 383 | 0.840 |
Why?
| | Heart-Assist Devices | 9 | 2024 | 567 | 0.840 |
Why?
| | Postoperative Complications | 13 | 2025 | 2920 | 0.820 |
Why?
| | Donor Selection | 3 | 2020 | 79 | 0.800 |
Why?
| | Graft Survival | 9 | 2025 | 526 | 0.790 |
Why?
| | Ventricular Dysfunction | 2 | 2013 | 16 | 0.760 |
Why?
| | Child, Preschool | 37 | 2025 | 11799 | 0.750 |
Why?
| | Blood Group Incompatibility | 3 | 2025 | 20 | 0.750 |
Why?
| | ABO Blood-Group System | 3 | 2025 | 57 | 0.720 |
Why?
| | Tissue Donors | 5 | 2020 | 424 | 0.720 |
Why?
| | Heterotaxy Syndrome | 1 | 2021 | 14 | 0.690 |
Why?
| | Retrospective Studies | 35 | 2025 | 17101 | 0.680 |
Why?
| | Neurodevelopmental Disorders | 2 | 2024 | 227 | 0.650 |
Why?
| | Immunosuppressive Agents | 6 | 2025 | 847 | 0.640 |
Why?
| | Marfan Syndrome | 2 | 2011 | 46 | 0.640 |
Why?
| | Follow-Up Studies | 19 | 2024 | 5417 | 0.630 |
Why?
| | Infant | 30 | 2025 | 10039 | 0.610 |
Why?
| | Societies, Medical | 3 | 2024 | 887 | 0.600 |
Why?
| | General Practice | 1 | 2019 | 32 | 0.590 |
Why?
| | Adolescent | 39 | 2025 | 22453 | 0.580 |
Why?
| | Coronary Vessels | 2 | 2018 | 251 | 0.570 |
Why?
| | Primary Graft Dysfunction | 1 | 2019 | 35 | 0.570 |
Why?
| | Aortic Aneurysm, Thoracic | 2 | 2011 | 139 | 0.570 |
Why?
| | Myocardium | 9 | 2023 | 939 | 0.550 |
Why?
| | Biopsy | 9 | 2024 | 1077 | 0.550 |
Why?
| | Medication Adherence | 2 | 2019 | 539 | 0.530 |
Why?
| | Humans | 91 | 2025 | 144957 | 0.520 |
Why?
| | Patient Selection | 3 | 2024 | 719 | 0.520 |
Why?
| | Ventricular Dysfunction, Left | 4 | 2024 | 392 | 0.490 |
Why?
| | Male | 61 | 2025 | 72406 | 0.480 |
Why?
| | Risk Factors | 17 | 2024 | 10792 | 0.480 |
Why?
| | Tissue and Organ Procurement | 6 | 2025 | 346 | 0.440 |
Why?
| | Echocardiography, Doppler | 2 | 2024 | 115 | 0.440 |
Why?
| | Female | 59 | 2025 | 78376 | 0.430 |
Why?
| | Ventricular Remodeling | 3 | 2024 | 276 | 0.420 |
Why?
| | Tacrolimus | 2 | 2025 | 196 | 0.410 |
Why?
| | Cardiomyopathy, Hypertrophic | 4 | 2023 | 145 | 0.400 |
Why?
| | Coronary Artery Disease | 2 | 2024 | 741 | 0.400 |
Why?
| | Transplant Recipients | 2 | 2025 | 180 | 0.380 |
Why?
| | Hemodynamics | 4 | 2022 | 1121 | 0.370 |
Why?
| | Genetic Testing | 4 | 2024 | 482 | 0.370 |
Why?
| | Vascular Remodeling | 1 | 2014 | 205 | 0.360 |
Why?
| | Arrhythmias, Cardiac | 3 | 2013 | 361 | 0.360 |
Why?
| | Treatment Outcome | 17 | 2025 | 11695 | 0.360 |
Why?
| | Death, Sudden, Cardiac | 2 | 2012 | 230 | 0.350 |
Why?
| | Aneurysm | 1 | 2011 | 37 | 0.350 |
Why?
| | Protein-Losing Enteropathies | 1 | 2011 | 10 | 0.340 |
Why?
| | American Heart Association | 3 | 2019 | 350 | 0.340 |
Why?
| | Electrocardiography | 2 | 2014 | 663 | 0.330 |
Why?
| | Organ Transplantation | 2 | 2024 | 248 | 0.320 |
Why?
| | Anemia, Iron-Deficiency | 1 | 2011 | 62 | 0.320 |
Why?
| | Aortic Valve | 2 | 2014 | 365 | 0.320 |
Why?
| | Defibrillators | 1 | 2010 | 23 | 0.310 |
Why?
| | Ventricular Fibrillation | 1 | 2010 | 64 | 0.310 |
Why?
| | Incidence | 7 | 2025 | 2883 | 0.290 |
Why?
| | Kidney Diseases | 2 | 2023 | 427 | 0.280 |
Why?
| | Ventricular Function, Left | 3 | 2024 | 541 | 0.280 |
Why?
| | Craniofacial Abnormalities | 1 | 2009 | 76 | 0.280 |
Why?
| | Mitral Valve | 1 | 2009 | 96 | 0.280 |
Why?
| | Infant, Newborn | 12 | 2024 | 6434 | 0.280 |
Why?
| | Tachycardia, Ventricular | 1 | 2010 | 181 | 0.270 |
Why?
| | Kidney Transplantation | 3 | 2023 | 704 | 0.270 |
Why?
| | Heart Ventricles | 4 | 2017 | 760 | 0.270 |
Why?
| | Predictive Value of Tests | 4 | 2024 | 2118 | 0.260 |
Why?
| | Severity of Illness Index | 6 | 2018 | 2925 | 0.260 |
Why?
| | Prognosis | 9 | 2024 | 4293 | 0.250 |
Why?
| | Allografts | 2 | 2024 | 150 | 0.240 |
Why?
| | Glomerular Filtration Rate | 3 | 2024 | 760 | 0.240 |
Why?
| | Aorta, Thoracic | 1 | 2009 | 286 | 0.240 |
Why?
| | Everolimus | 1 | 2025 | 111 | 0.220 |
Why?
| | Perioperative Care | 2 | 2017 | 231 | 0.220 |
Why?
| | Mycophenolic Acid | 1 | 2025 | 120 | 0.220 |
Why?
| | Transplants | 2 | 2022 | 39 | 0.220 |
Why?
| | Peripheral Arterial Disease | 1 | 2011 | 503 | 0.220 |
Why?
| | Young Adult | 15 | 2024 | 14126 | 0.210 |
Why?
| | Vascular Resistance | 3 | 2014 | 367 | 0.210 |
Why?
| | Time Factors | 7 | 2024 | 7183 | 0.210 |
Why?
| | Risk Assessment | 4 | 2023 | 3676 | 0.210 |
Why?
| | Adult | 24 | 2024 | 40506 | 0.200 |
Why?
| | Genetic Counseling | 1 | 2024 | 81 | 0.200 |
Why?
| | Delayed-Action Preparations | 1 | 2024 | 183 | 0.200 |
Why?
| | Databases, Factual | 1 | 2009 | 1486 | 0.200 |
Why?
| | Heart | 3 | 2023 | 636 | 0.200 |
Why?
| | Palliative Care | 1 | 2012 | 1008 | 0.200 |
Why?
| | Transplantation, Homologous | 3 | 2021 | 415 | 0.190 |
Why?
| | Bacterial Infections | 1 | 2025 | 246 | 0.190 |
Why?
| | Contrast Media | 2 | 2023 | 488 | 0.180 |
Why?
| | Inheritance Patterns | 1 | 2022 | 44 | 0.180 |
Why?
| | Hypoplastic Left Heart Syndrome | 2 | 2014 | 120 | 0.180 |
Why?
| | Practice Patterns, Physicians' | 2 | 2024 | 1358 | 0.180 |
Why?
| | Renal Insufficiency, Chronic | 2 | 2025 | 653 | 0.170 |
Why?
| | Magnetic Resonance Imaging, Cine | 3 | 2023 | 214 | 0.170 |
Why?
| | Echocardiography | 6 | 2018 | 652 | 0.170 |
Why?
| | Exome | 1 | 2022 | 227 | 0.160 |
Why?
| | Drug Monitoring | 2 | 2024 | 395 | 0.160 |
Why?
| | Prospective Studies | 7 | 2023 | 7997 | 0.160 |
Why?
| | Phenotype | 4 | 2022 | 3164 | 0.160 |
Why?
| | United States | 15 | 2025 | 15988 | 0.160 |
Why?
| | Genetic Predisposition to Disease | 4 | 2022 | 2365 | 0.150 |
Why?
| | Noonan Syndrome | 1 | 2019 | 14 | 0.150 |
Why?
| | Respiratory Insufficiency | 1 | 2023 | 326 | 0.150 |
Why?
| | Clinical Decision-Making | 1 | 2022 | 359 | 0.150 |
Why?
| | Pneumonia | 1 | 2025 | 631 | 0.140 |
Why?
| | Attention Deficit Disorder with Hyperactivity | 1 | 2023 | 428 | 0.140 |
Why?
| | Hyperplasia | 1 | 2018 | 174 | 0.140 |
Why?
| | Proportional Hazards Models | 7 | 2017 | 1325 | 0.140 |
Why?
| | Neuropsychological Tests | 2 | 2021 | 1137 | 0.140 |
Why?
| | Child Nutrition Disorders | 1 | 2018 | 20 | 0.140 |
Why?
| | Global Health | 1 | 2021 | 401 | 0.140 |
Why?
| | Surgical Wound Dehiscence | 1 | 2017 | 19 | 0.130 |
Why?
| | Survival Analysis | 4 | 2021 | 1385 | 0.130 |
Why?
| | Cohort Studies | 6 | 2022 | 5965 | 0.130 |
Why?
| | Kaplan-Meier Estimate | 2 | 2017 | 966 | 0.130 |
Why?
| | Kidney Failure, Chronic | 1 | 2023 | 598 | 0.130 |
Why?
| | Cognition Disorders | 1 | 2021 | 538 | 0.120 |
Why?
| | Genotype | 1 | 2022 | 1835 | 0.120 |
Why?
| | Death | 1 | 2017 | 131 | 0.120 |
Why?
| | Age Factors | 3 | 2024 | 3335 | 0.120 |
Why?
| | Executive Function | 1 | 2021 | 461 | 0.120 |
Why?
| | Extracorporeal Circulation | 1 | 2016 | 15 | 0.120 |
Why?
| | Myocardial Contraction | 2 | 2024 | 298 | 0.120 |
Why?
| | Sirolimus | 1 | 2017 | 281 | 0.120 |
Why?
| | Isolated Noncompaction of the Ventricular Myocardium | 1 | 2015 | 4 | 0.120 |
Why?
| | Cardio-Renal Syndrome | 1 | 2015 | 18 | 0.110 |
Why?
| | Genes, Neurofibromatosis 1 | 1 | 2015 | 4 | 0.110 |
Why?
| | Pseudarthrosis | 1 | 2015 | 14 | 0.110 |
Why?
| | Fluorescent Antibody Technique | 1 | 2015 | 370 | 0.110 |
Why?
| | Neurofibromatosis 1 | 1 | 2015 | 54 | 0.110 |
Why?
| | Surgical Wound Infection | 1 | 2017 | 316 | 0.110 |
Why?
| | Cardiology | 1 | 2017 | 353 | 0.110 |
Why?
| | Tachycardia | 1 | 2014 | 57 | 0.100 |
Why?
| | Pulmonary Wedge Pressure | 1 | 2014 | 67 | 0.100 |
Why?
| | Cardiovascular Diseases | 3 | 2012 | 2171 | 0.100 |
Why?
| | Sequence Deletion | 1 | 2014 | 193 | 0.100 |
Why?
| | Hospitals, Pediatric | 1 | 2017 | 557 | 0.100 |
Why?
| | T-Box Domain Proteins | 1 | 2014 | 106 | 0.100 |
Why?
| | Tibia | 1 | 2015 | 176 | 0.100 |
Why?
| | Referral and Consultation | 1 | 2019 | 853 | 0.100 |
Why?
| | Pediatrics | 3 | 2016 | 1115 | 0.100 |
Why?
| | Arterial Pressure | 1 | 2014 | 136 | 0.100 |
Why?
| | Age Distribution | 1 | 2014 | 403 | 0.100 |
Why?
| | Sex Distribution | 1 | 2014 | 386 | 0.100 |
Why?
| | Cardiomyopathy, Restrictive | 1 | 2012 | 11 | 0.090 |
Why?
| | Gene Expression Regulation | 1 | 2022 | 2609 | 0.090 |
Why?
| | Reoperation | 2 | 2021 | 631 | 0.090 |
Why?
| | Abnormalities, Multiple | 1 | 2014 | 197 | 0.090 |
Why?
| | Immunoglobulins | 1 | 2012 | 160 | 0.090 |
Why?
| | Fibrosis | 3 | 2023 | 548 | 0.090 |
Why?
| | Middle Aged | 13 | 2017 | 35928 | 0.090 |
Why?
| | Altitude Sickness | 1 | 2013 | 141 | 0.090 |
Why?
| | International Cooperation | 1 | 2012 | 198 | 0.090 |
Why?
| | Liver Diseases | 1 | 2014 | 304 | 0.090 |
Why?
| | Glucaric Acid | 1 | 2011 | 4 | 0.090 |
Why?
| | Anxiety | 1 | 2019 | 1110 | 0.090 |
Why?
| | Cardiotonic Agents | 1 | 2011 | 95 | 0.080 |
Why?
| | Tissue and Organ Harvesting | 1 | 2011 | 73 | 0.080 |
Why?
| | Hematinics | 1 | 2011 | 22 | 0.080 |
Why?
| | Capillaries | 1 | 2012 | 124 | 0.080 |
Why?
| | Treatment Failure | 1 | 2012 | 365 | 0.080 |
Why?
| | Hypertrophy, Left Ventricular | 1 | 2011 | 124 | 0.080 |
Why?
| | Ferric Compounds | 1 | 2011 | 55 | 0.080 |
Why?
| | Stroke Volume | 1 | 2014 | 651 | 0.080 |
Why?
| | Adrenergic alpha-Antagonists | 1 | 2010 | 34 | 0.080 |
Why?
| | Echocardiography, Doppler, Color | 1 | 2010 | 38 | 0.080 |
Why?
| | Delivery of Health Care | 1 | 2017 | 947 | 0.080 |
Why?
| | Diverticulum | 1 | 2010 | 14 | 0.080 |
Why?
| | Propanolamines | 1 | 2010 | 40 | 0.080 |
Why?
| | Pediatric Obesity | 1 | 2018 | 638 | 0.080 |
Why?
| | Healthcare Disparities | 1 | 2017 | 728 | 0.080 |
Why?
| | Carbazoles | 1 | 2010 | 56 | 0.080 |
Why?
| | Kidney Function Tests | 2 | 2024 | 157 | 0.080 |
Why?
| | Disease Management | 1 | 2014 | 647 | 0.080 |
Why?
| | Negative-Pressure Wound Therapy | 1 | 2009 | 28 | 0.080 |
Why?
| | Magnetic Resonance Angiography | 1 | 2011 | 251 | 0.080 |
Why?
| | Recovery of Function | 1 | 2014 | 710 | 0.080 |
Why?
| | Blood Component Transfusion | 1 | 2010 | 103 | 0.080 |
Why?
| | Heart-Lung Transplantation | 2 | 2024 | 13 | 0.070 |
Why?
| | Mutation | 3 | 2019 | 4099 | 0.070 |
Why?
| | Resource Allocation | 1 | 2009 | 53 | 0.070 |
Why?
| | Dopamine | 1 | 2011 | 289 | 0.070 |
Why?
| | Syndrome | 1 | 2009 | 380 | 0.070 |
Why?
| | Immune Tolerance | 1 | 2010 | 379 | 0.070 |
Why?
| | Pulmonary Artery | 1 | 2014 | 1134 | 0.070 |
Why?
| | Cross-Sectional Studies | 1 | 2019 | 5872 | 0.070 |
Why?
| | Multivariate Analysis | 3 | 2017 | 1540 | 0.070 |
Why?
| | Risk | 1 | 2010 | 911 | 0.060 |
Why?
| | Connexin 43 | 1 | 2007 | 36 | 0.060 |
Why?
| | Heart Valve Prosthesis Implantation | 1 | 2009 | 197 | 0.060 |
Why?
| | Health Care Surveys | 2 | 2020 | 539 | 0.060 |
Why?
| | Defibrillators, Implantable | 1 | 2010 | 382 | 0.060 |
Why?
| | Wound Healing | 1 | 2009 | 351 | 0.060 |
Why?
| | Arrhythmogenic Right Ventricular Dysplasia | 1 | 2007 | 60 | 0.060 |
Why?
| | Morbidity | 2 | 2021 | 323 | 0.060 |
Why?
| | Health Policy | 1 | 2009 | 401 | 0.060 |
Why?
| | Cadherins | 1 | 2007 | 201 | 0.060 |
Why?
| | Patient Compliance | 1 | 2010 | 589 | 0.060 |
Why?
| | Dose-Response Relationship, Drug | 2 | 2025 | 2032 | 0.060 |
Why?
| | Lymphoproliferative Disorders | 1 | 2025 | 57 | 0.060 |
Why?
| | Surveys and Questionnaires | 3 | 2024 | 6053 | 0.060 |
Why?
| | Biomarkers | 4 | 2023 | 4275 | 0.060 |
Why?
| | Tomography, X-Ray Computed | 2 | 2014 | 2738 | 0.060 |
Why?
| | Canada | 2 | 2017 | 428 | 0.050 |
Why?
| | Cytomegalovirus Infections | 1 | 2025 | 206 | 0.050 |
Why?
| | Area Under Curve | 1 | 2024 | 331 | 0.050 |
Why?
| | Gadolinium | 1 | 2023 | 84 | 0.050 |
Why?
| | Calcineurin Inhibitors | 1 | 2022 | 69 | 0.050 |
Why?
| | Drug Therapy, Combination | 1 | 2025 | 1048 | 0.050 |
Why?
| | Myocytes, Cardiac | 1 | 2007 | 556 | 0.050 |
Why?
| | Cause of Death | 2 | 2015 | 472 | 0.040 |
Why?
| | Biomechanical Phenomena | 1 | 2024 | 842 | 0.040 |
Why?
| | Living Donors | 1 | 2023 | 280 | 0.040 |
Why?
| | Quality of Life | 2 | 2023 | 3192 | 0.040 |
Why?
| | Utah | 2 | 2012 | 81 | 0.040 |
Why?
| | Aged | 4 | 2017 | 25947 | 0.040 |
Why?
| | Age of Onset | 1 | 2022 | 551 | 0.040 |
Why?
| | Recombinant Fusion Proteins | 1 | 2022 | 675 | 0.040 |
Why?
| | Proto-Oncogene Proteins c-raf | 1 | 2019 | 45 | 0.040 |
Why?
| | Protein Tyrosine Phosphatase, Non-Receptor Type 11 | 1 | 2019 | 22 | 0.040 |
Why?
| | Logistic Models | 1 | 2024 | 2119 | 0.040 |
Why?
| | Genes, ras | 1 | 2019 | 96 | 0.040 |
Why?
| | Immunity, Cellular | 2 | 2012 | 272 | 0.040 |
Why?
| | ras Proteins | 1 | 2019 | 151 | 0.030 |
Why?
| | Postoperative Period | 1 | 2019 | 354 | 0.030 |
Why?
| | Prevalence | 2 | 2015 | 2836 | 0.030 |
Why?
| | Machine Learning | 1 | 2023 | 587 | 0.030 |
Why?
| | Brazil | 1 | 2017 | 180 | 0.030 |
Why?
| | Adenoidectomy | 1 | 2017 | 81 | 0.030 |
Why?
| | Longitudinal Studies | 1 | 2024 | 2947 | 0.030 |
Why?
| | Sample Size | 1 | 2017 | 123 | 0.030 |
Why?
| | Genetic Variation | 1 | 2022 | 984 | 0.030 |
Why?
| | Education, Medical, Continuing | 1 | 2017 | 132 | 0.030 |
Why?
| | United Kingdom | 1 | 2017 | 338 | 0.030 |
Why?
| | Gadolinium DTPA | 1 | 2016 | 68 | 0.030 |
Why?
| | Drug Administration Schedule | 1 | 2017 | 783 | 0.030 |
Why?
| | Kidney | 1 | 2023 | 1496 | 0.030 |
Why?
| | Tonsillectomy | 1 | 2017 | 105 | 0.030 |
Why?
| | Health Services Needs and Demand | 1 | 2017 | 280 | 0.030 |
Why?
| | Adaptation, Psychological | 1 | 2021 | 717 | 0.030 |
Why?
| | Antibodies, Monoclonal | 1 | 2022 | 1524 | 0.030 |
Why?
| | Analysis of Variance | 1 | 2018 | 1311 | 0.030 |
Why?
| | Orthopedic Procedures | 1 | 2017 | 243 | 0.030 |
Why?
| | Gene Expression Profiling | 1 | 2022 | 1786 | 0.030 |
Why?
| | Lower Extremity Deformities, Congenital | 1 | 2014 | 3 | 0.030 |
Why?
| | Upper Extremity Deformities, Congenital | 1 | 2014 | 6 | 0.030 |
Why?
| | Cardiovascular Surgical Procedures | 1 | 2014 | 30 | 0.030 |
Why?
| | Comparative Genomic Hybridization | 1 | 2014 | 28 | 0.030 |
Why?
| | Breast Diseases | 1 | 2014 | 22 | 0.030 |
Why?
| | Dilatation, Pathologic | 1 | 2014 | 62 | 0.030 |
Why?
| | Comorbidity | 1 | 2019 | 1660 | 0.030 |
Why?
| | Anti-Bacterial Agents | 1 | 2025 | 1915 | 0.030 |
Why?
| | Ulna | 1 | 2014 | 35 | 0.030 |
Why?
| | Case-Control Studies | 1 | 2022 | 3608 | 0.030 |
Why?
| | Aortic Valve Insufficiency | 1 | 2014 | 43 | 0.030 |
Why?
| | Drug Therapy | 1 | 2014 | 80 | 0.030 |
Why?
| | ROC Curve | 1 | 2016 | 615 | 0.030 |
Why?
| | Acute Disease | 1 | 2017 | 1031 | 0.030 |
Why?
| | DNA Mutational Analysis | 1 | 2015 | 409 | 0.030 |
Why?
| | Pandemics | 1 | 2022 | 1695 | 0.030 |
Why?
| | Practice Guidelines as Topic | 1 | 2022 | 1563 | 0.030 |
Why?
| | Preoperative Period | 1 | 2014 | 149 | 0.030 |
Why?
| | Heart Septal Defects, Atrial | 1 | 2014 | 59 | 0.020 |
Why?
| | Radiography | 1 | 2015 | 845 | 0.020 |
Why?
| | Genetic Association Studies | 1 | 2014 | 373 | 0.020 |
Why?
| | Statistics as Topic | 1 | 2013 | 284 | 0.020 |
Why?
| | Population Dynamics | 1 | 2013 | 158 | 0.020 |
Why?
| | Coronary Angiography | 1 | 2014 | 323 | 0.020 |
Why?
| | Antigens, CD34 | 1 | 2012 | 88 | 0.020 |
Why?
| | Coronary Circulation | 1 | 2012 | 136 | 0.020 |
Why?
| | Cardiac Surgical Procedures | 1 | 2017 | 609 | 0.020 |
Why?
| | Brain Death | 1 | 2011 | 60 | 0.020 |
Why?
| | Complement C4b | 1 | 2010 | 9 | 0.020 |
Why?
| | Patient Acceptance of Health Care | 1 | 2017 | 886 | 0.020 |
Why?
| | Necrosis | 1 | 2011 | 244 | 0.020 |
Why?
| | Randomized Controlled Trials as Topic | 1 | 2017 | 1721 | 0.020 |
Why?
| | Complement C3d | 1 | 2010 | 67 | 0.020 |
Why?
| | Diastole | 1 | 2010 | 143 | 0.020 |
Why?
| | Systole | 1 | 2010 | 178 | 0.020 |
Why?
| | Ultrasonography | 1 | 2014 | 770 | 0.020 |
Why?
| | Fibrin | 1 | 2010 | 91 | 0.020 |
Why?
| | Chronic Disease | 1 | 2016 | 1813 | 0.020 |
Why?
| | Fibrinolytic Agents | 1 | 2012 | 292 | 0.020 |
Why?
| | HLA-DR Antigens | 1 | 2010 | 220 | 0.020 |
Why?
| | Attitude of Health Personnel | 1 | 2017 | 1186 | 0.020 |
Why?
| | Reproducibility of Results | 1 | 2017 | 3415 | 0.020 |
Why?
| | Isoantibodies | 1 | 2008 | 57 | 0.020 |
Why?
| | Ischemia | 1 | 2011 | 421 | 0.020 |
Why?
| | Oxygen | 1 | 2013 | 995 | 0.020 |
Why?
| | Image Processing, Computer-Assisted | 1 | 2012 | 781 | 0.020 |
Why?
| | Cytoskeletal Proteins | 1 | 2007 | 156 | 0.020 |
Why?
| | Peptide Fragments | 1 | 2010 | 699 | 0.020 |
Why?
| | Gap Junctions | 1 | 2007 | 67 | 0.020 |
Why?
| | Regression Analysis | 1 | 2008 | 1003 | 0.010 |
Why?
| | Dogs | 1 | 2007 | 438 | 0.010 |
Why?
| | Disease Progression | 1 | 2013 | 2852 | 0.010 |
Why?
| | Blotting, Western | 1 | 2007 | 1187 | 0.010 |
Why?
| | Sequence Analysis, DNA | 1 | 2007 | 824 | 0.010 |
Why?
| | Stroke | 1 | 2012 | 1258 | 0.010 |
Why?
| | Magnetic Resonance Imaging | 1 | 2014 | 3869 | 0.010 |
Why?
| | Disease Models, Animal | 1 | 2007 | 4569 | 0.010 |
Why?
| | Animals | 1 | 2007 | 38109 | 0.000 |
Why?
|
|
Everitt's Networks
Click the "See All" links for more information and interactive visualizations!
Concepts  Derived automatically from this person's publications. _
Co-Authors People in Profiles who have published with this person. _
Similar People People who share similar concepts with this person. _
Same Department
People who are also in this person's primary department.
Physical Neighbors People whose addresses are nearby this person. _
|